Brii Biosciences Limited Stock Net Income
| BRIBF Stock | USD 0.19 0.00 0.00% |
As of the 15th of February 2026, Brii Biosciences shows the Standard Deviation of 2.56, risk adjusted performance of (0.09), and Mean Deviation of 0.6217. Brii Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Brii Biosciences coefficient of variation, total risk alpha, as well as the relationship between the Total Risk Alpha and skewness to decide if Brii Biosciences is priced correctly, providing market reflects its regular price of 0.19 per share. As Brii Biosciences appears to be a penny stock we also recommend to validate its information ratio numbers.
Brii Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Brii Biosciences' valuation are provided below:Brii Biosciences Limited does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Brii |
Brii Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Brii Biosciences' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Brii Biosciences.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Brii Biosciences on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Brii Biosciences Limited or generate 0.0% return on investment in Brii Biosciences over 90 days. Brii Biosciences is related to or competes with NDT Pharmaceuticals, Molecular Partners, Innate Pharma, NervGen Pharma, JW (Cayman), Scancell Holdings, and BICO Group. Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous sys... More
Brii Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Brii Biosciences' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Brii Biosciences Limited upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 20.83 |
Brii Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Brii Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Brii Biosciences' standard deviation. In reality, there are many statistical measures that can use Brii Biosciences historical prices to predict the future Brii Biosciences' volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | (0.52) | |||
| Treynor Ratio | 6.97 |
Brii Biosciences February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | 6.98 | |||
| Mean Deviation | 0.6217 | |||
| Coefficient Of Variation | (812.40) | |||
| Standard Deviation | 2.56 | |||
| Variance | 6.58 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.32) | |||
| Total Risk Alpha | (0.52) | |||
| Treynor Ratio | 6.97 | |||
| Maximum Drawdown | 20.83 | |||
| Skewness | (8.12) | |||
| Kurtosis | 66.0 |
Brii Biosciences Backtested Returns
Brii Biosciences secures Sharpe Ratio (or Efficiency) of -0.12, which signifies that the company had a -0.12 % return per unit of risk over the last 3 months. Brii Biosciences Limited exposes sixteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Brii Biosciences' Standard Deviation of 2.56, risk adjusted performance of (0.09), and Mean Deviation of 0.6217 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.0467, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Brii Biosciences are expected to decrease at a much lower rate. During the bear market, Brii Biosciences is likely to outperform the market. At this point, Brii Biosciences has a negative expected return of -0.33%. Please make sure to confirm Brii Biosciences' information ratio, as well as the relationship between the skewness and day median price , to decide if Brii Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.00 |
No correlation between past and present
Brii Biosciences Limited has no correlation between past and present. Overlapping area represents the amount of predictability between Brii Biosciences time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Brii Biosciences price movement. The serial correlation of 0.0 indicates that just 0.0% of current Brii Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 0.21 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Brii Biosciences Limited reported net income of (4.16 Billion). This is 1320.06% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The net income for all United States stocks is significantly higher than that of the company.
Brii Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Brii Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Brii Biosciences could also be used in its relative valuation, which is a method of valuing Brii Biosciences by comparing valuation metrics of similar companies.Brii Biosciences is currently under evaluation in net income category among its peers.
Brii Fundamentals
| Return On Equity | -5.34 | |||
| Return On Asset | -0.19 | |||
| Operating Margin | (10.33) % | |||
| Current Valuation | 305.78 M | |||
| Shares Outstanding | 723.35 M | |||
| Shares Owned By Insiders | 5.41 % | |||
| Shares Owned By Institutions | 53.10 % | |||
| Price To Book | 0.95 X | |||
| Price To Sales | 10.64 X | |||
| Gross Profit | 92.54 M | |||
| EBITDA | (4.18 B) | |||
| Net Income | (4.16 B) | |||
| Cash And Equivalents | 3.22 B | |||
| Cash Per Share | 4.45 X | |||
| Total Debt | 17.47 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 10.68 X | |||
| Book Value Per Share | 4.43 X | |||
| Cash Flow From Operations | (879.46 M) | |||
| Earnings Per Share | (1.42) X | |||
| Number Of Employees | 123 | |||
| Market Capitalization | 941.75 M | |||
| Total Asset | 3.61 B | |||
| Z Score | 28.5 | |||
| Net Asset | 3.61 B |
About Brii Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Brii Biosciences Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brii Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brii Biosciences Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Brii Pink Sheet
Brii Biosciences financial ratios help investors to determine whether Brii Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Brii with respect to the benefits of owning Brii Biosciences security.